Gilead Sciences is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines for areas of unmet medical need. They are global leaders in antiviral therapies for HIV and hepatitis, with a growing presence in oncology and inflammatory diseases.
Gilead transforms serious illnesses into manageable or curable conditions by developing 'first-in-class' and 'best-in-class' high-science therapies that redefine the standard of care.
AI Visibility Score
Gilead Sciences, Inc. has an AI visibility score of 70/100, rated as good. This score reflects how often and how prominently Gilead Sciences, Inc. appears in responses from AI assistants like ChatGPT, Claude, and Gemini.
AI Perception Summary
Gilead Sciences maintains a consistent presence among patients and institutional stakeholders, yet remains largely absent from critical therapy-selection conversations where competitors capture top-tier visibility. While the brand is effectively positioned as a trusted leader for patient researchers, it is missing vital opportunities to establish authority within AI-driven oncology and antiviral treatment recommendation engines.
Strengths
- Successfully established brand authority among the Chronically Ill Patient Researcher persona.
- Achieved a 100% mention rate within AI Overviews for core and adjacent thematic queries.
- Positive sentiment alignment among institutional payers, indicating strong trust in current strategic positioning.
Visibility Gaps
- Total absence in therapy-selection queries, allowing competitors like Breyanzi, Kymriah, and Tecartus to dominate clinical decision support.
- Missed visibility in Hospital Formulary Committee Lead inquiries, representing a critical disconnect with key institutional decision-makers.
- Failure to trigger in general brand 'vibe check' inquiries, indicating a lack of foundational digital footprint for broader corporate recognition.
Competitors in AI Recommendations
- Breyanzi: 1 mentions
- Kymriah: 1 mentions
- Tecartus: 1 mentions
- Roche (Genentech): 1 mentions
- AstraZeneca (Tagrisso, Enhertu): 1 mentions
- Novartis: 1 mentions
- Pfizer (Ibrance, Xtandi): 1 mentions
- Johnson & Johnson (J&J Innovative Medicine, Darzalex, Erleada): 1 mentions
- Merck & Co. (Keytruda, Lynparza): 1 mentions
- Bristol Myers Squibb (BMS, Abecma, Breyanzi): 1 mentions
- Eli Lilly (Verzenio, Retevmo): 1 mentions
- Exelixis: 1 mentions
- Daiichi Sankyo (Dato-DXd): 1 mentions
- Camizestrant: 1 mentions
- Gedatolisib: 1 mentions
Categories: Biotechnology / Pharmaceuticals